Troy Edward Wilson serves as president and CEO of Kura Oncology (KURA). His Form 4 filing, a report of insider stock trades, was filed on November 17, 2026. The earliest purchase date was November 13, and the latest was November 16.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-13 |
| Date of Latest Transaction | 2026-11-16 |
| Buy/Sell | buy |
| Transaction Count | 2 |
| Shares Transacted | 200,000 |
| Price | $7.52 |
| Total Transaction Value | $1,504,765.01 |
| Insider | |
| Ticker Symbol | KURA |
| Company | Kura Oncology, Inc. |
| Insider Name | WILSON TROY EDWARD |
| Insider Title | President and CEO |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 679,194 |
| Position Size Change | 29.45% |
| Filing | |
| Filing Date | 2026-11-17 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were purchases of company shares, reported with transaction code P. The activity covers two transactions by one insider in a single filing.
What was the average price of the transaction?
The average price was $7.52 per share when rounded to cents. The more precise figure was $7.52382505 per share. Prices for each of the two purchases were not provided separately.
How did this transaction affect the insider's holdings?
The purchases added 200,000 shares, leaving 679,194 reported shares owned afterward. The purchased shares make up 29.45% of that total, or about 29 of every 100 shares owned after the purchases.
What's the total transaction value?
The total value was $1,504,765.01 for both purchases together. That amount covers all 200,000 shares bought across the two transactions.
Are there any special circumstances around this transaction?
The available transaction information did not identify a special arrangement for these purchases. Filing footnotes were not provided, so any further explanation or terms remain unknown.
For research purposes only; not investment advice.